The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...
By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...
Pfizer BioNTech halt COVID vaccine study in adults 50-64 due to slow enrollment, citing inability to generate relevant postmarketing data.
1don MSN
'Felt like I was dying': Elon Musk supports Pfizer insider who said Covid vaccine killed thousands
Sterz also cited figures from Germany’s vaccine safety monitoring system, managed by the Paul-Ehrlich-Institut, stating that ...
The move comes as COVID vaccine makers grapple with pushback from the U.S. administration and weak U.S. demand for the ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
BioNTech will wind up its vaccine manufacturing plant in Singapore by February 2027 after a strategic review. Read more at ...
Pfizer and BioNTech have stopped their large U.S. COVID-19 vaccine trial in adults aged 50 to 64, citing insufficient ...
The Trump administration has also pushed back against Covid vaccine recommendations, and the FDA toughened its requirements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results